{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T17:00:35Z","timestamp":1758819635582},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,3]]},"DOI":"10.7759\/cureus.61577","type":"journal-article","created":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T12:53:38Z","timestamp":1717419218000},"source":"Crossref","is-referenced-by-count":1,"title":["Rapid Improvement in Weight, Body Composition, and Glucose Variability With Semaglutide in Type 1 Diabetes"],"prefix":"10.7759","author":[{"given":"Hoda","family":"Gad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rayaz A","family":"Malik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art","volume":"46","author":"Nauck MA","year":"2021","unstructured":"Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab. 2021, 46:101102. 10.1016\/j.molmet.2020.101102","journal-title":"Mol Metab"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial","volume":"325","author":"Rubino D","year":"2021","unstructured":"Rubino D, Abrahamsson N, Davies M, et al.. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021, 325:1414-25. 10.1001\/jama.2021.3224","journal-title":"JAMA"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-021-09699-1","article-title":"Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes","volume":"23","author":"Mahapatra MK","year":"2022","unstructured":"Mahapatra MK, Karuppasamy M, Sahoo BM. Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes. Rev Endocr Metab Disord. 2022, 23:521-39. 10.1007\/s11154-021-09699-1","journal-title":"Rev Endocr Metab Disord"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1210\/jcemcr\/luac017","article-title":"Glucagon-like peptide-1 receptor agonist treatment with semaglutide in type 1 diabetes","volume":"1","author":"Raven LM","year":"2023","unstructured":"Raven LM, Greenfield JR, Muir CA. Glucagon-like peptide-1 receptor agonist treatment with semaglutide in type 1 diabetes. JCEM Case Rep. 2023, 1:luac017. 10.1210\/jcemcr\/luac017","journal-title":"JCEM Case Rep"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2337\/dci19-0028","article-title":"Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range","volume":"42","author":"Battelino T","year":"2019","unstructured":"Battelino T, Danne T, Bergenstal RM, et al.. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care. 2019, 42:1593-603. 10.2337\/dci19-0028","journal-title":"Diabetes Care"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14532","article-title":"Efficacy and safety of liraglutide in type 1 diabetes by baseline characteristics in the ADJUNCT ONE and ADJUNCT TWO randomized controlled trials","volume":"23","author":"Dejgaard TF","year":"2021","unstructured":"Dejgaard TF, von Scholten BJ, Christiansen E, et al.. Efficacy and safety of liraglutide in type 1 diabetes by baseline characteristics in the ADJUNCT ONE and ADJUNCT TWO randomized controlled trials. Diabetes Obes Metab. 2021, 23:2752-62. 10.1111\/dom.14532","journal-title":"Diabetes Obes Metab"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31506-X","article-title":"Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study","volume":"392","author":"Rawshani A","year":"2018","unstructured":"Rawshani A, Sattar N, Franz\u00e9n S, et al.. Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study. Lancet. 2018, 392:477-86. 10.1016\/S0140-6736(18)31506-X","journal-title":"Lancet"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1177\/14791641221103217","article-title":"Glucose variability is associated with an adverse vascular profile but only in the presence of insulin resistance in individuals with type 1 diabetes: an observational study","volume":"19","author":"Kietsiriroje N","year":"2022","unstructured":"Kietsiriroje N, Pearson SM, O'Mahoney LL, West DJ, Ari\u00ebns RA, Ajjan RA, Campbell MD. Glucose variability is associated with an adverse vascular profile but only in the presence of insulin resistance in individuals with type 1 diabetes: an observational study. Diab Vasc Dis Res. 2022, 19:14791641221103217. 10.1177\/14791641221103217","journal-title":"Diab Vasc Dis Res"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-1167","article-title":"Excess BMI accelerates islet autoimmunity in older children and adolescents","volume":"43","author":"Ferrara-Cook C","year":"2020","unstructured":"Ferrara-Cook C, Geyer SM, Evans-Molina C, Libman IM, Becker DJ, Gitelman SE, Redondo MJ. Excess BMI accelerates islet autoimmunity in older children and adolescents. Diabetes Care. 2020, 43:580-7. 10.2337\/dc19-1167","journal-title":"Diabetes Care"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.4158\/EP13065.OR","article-title":"Liraglutide as additional treatment to insulin in obese patients with type 1 diabetes mellitus","volume":"19","author":"Kuhadiya ND","year":"2013","unstructured":"Kuhadiya ND, Malik R, Bellini NJ, Patterson JL, Traina A, Makdissi A, Dandona P. Liraglutide as additional treatment to insulin in obese patients with type 1 diabetes mellitus. Endocr Pract. 2013, 19:963-7. 10.4158\/EP13065.OR","journal-title":"Endocr Pract"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-023-05975-8","article-title":"SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study","volume":"66","author":"Anson M","year":"2023","unstructured":"Anson M, Zhao SS, Austin P, Ibarburu GH, Malik RA, Alam U. SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study. Diabetologia. 2023, 66:1869-81. 10.1007\/s00125-023-05975-8","journal-title":"Diabetologia"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2021.10601","article-title":"Future perspectives in diabesity treatment: semaglutide, a glucagon-like peptide 1 receptor agonist (Review)","volume":"22","author":"Tilinca MC","year":"2021","unstructured":"Tilinca MC, Tiuca RA, Niculas C, Varga A, Tilea I. Future perspectives in diabesity treatment: semaglutide, a glucagon-like peptide 1 receptor agonist (Review). Exp Ther Med. 2021, 22:1167. 10.3892\/etm.2021.10601","journal-title":"Exp Ther Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2024.111593","article-title":"Effect of low dose semaglutide in people with type 1 diabetes and excess weight","volume":"209","author":"Grassi BA","year":"2024","unstructured":"Grassi BA, Teresa Onetto M, S\u00e1nchez C, Tapia N, Mena F. Effect of low dose semaglutide in people with type 1 diabetes and excess weight. Diabetes Res Clin Pract. 2024, 209:111593. 10.1016\/j.diabres.2024.111593","journal-title":"Diabetes Res Clin Pract"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/253041-rapid-improvement-in-weight-body-composition-and-glucose-variability-with-semaglutide-in-type-1-diabetes","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T12:53:41Z","timestamp":1717419221000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/253041-rapid-improvement-in-weight-body-composition-and-glucose-variability-with-semaglutide-in-type-1-diabetes"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,3]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.61577","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,3]]}}}